Tango Therapeutics Plans 300-Patient Vopimetostat Second-Line Pancreatic Trial with FDA Support
Tango Therapeutics plans a 300-patient randomized second-line pancreatic cancer trial of PRMT5 inhibitor vopimetostat with hierarchical PFS then OS endpoints, with FDA support and sites in the U.S., Europe and Asia-Pacific, launching this year. Preclinical synergy and strong enrollment spurred RAS inhibitor combination studies with 14 and 16 patients enrolled.
1. Pivotal Pancreatic Cancer Trial
Tango Therapeutics will initiate a 300-patient randomized trial in second-line pancreatic cancer comparing vopimetostat against chemotherapy, with a hierarchical endpoint structure evaluating progression-free survival first and overall survival second, targeting a study launch this year.
2. FDA Support and Global Footprint
Late-year interactions with the FDA secured support for the trial’s design, statistical analysis plan, dose selection rationale and sample size, and the study will enroll patients across the U.S., Europe and Asia-Pacific to facilitate rapid recruitment.
3. RAS Inhibitor Combination Program
Building on preclinical synergy findings, Tango is testing vopimetostat alongside Revolution Medicines’ pan-RAS inhibitor daraxonrasib and KRAS G12D inhibitor zoldonrasib, with 14 patients in the daraxonrasib arm and 16 in the zoldonrasib arm, though clinical data remain immature.
4. Broader Pipeline and Upcoming Data
Tango’s CNS candidate TNG456 has entered dose escalation for GBM and NSCLC cohorts, a tumor-agnostic MTAP-deleted study is ongoing, and the company plans to release updated monotherapy and abemaciclib combination data later this year.